Dual-target CAR-NK cells
Phase 1Cell therapy
Dual-target CAR-NK cells is one of 90 biologic programs targeting Breast Cancer. It is currently in Phase 1.
3
Indications
4
Total Trials
4
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Adenocard
AstellasPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Dual-target CAR-NK cells
BBeijing Biotech
Phase 1
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Promestriene
UUniversity of Sao Paulo General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced NSCLC1 trial
Glioblastoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dual-target CAR-NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing Biotech